Cobalt-Catalyzed Cross-Dehydrogenative C(sp<sup>2</sup>
)−C(sp<sup>3</sup>
) Coupling of Oxazole/Thiazole with Ether or Cycloalkane
作者:Xiaojiao Wang、Bowen Lei、Lifang Ma、Lisi Zhu、Xinyue Zhang、Hao Zuo、Dailin Zhuang、Ziyuan Li
DOI:10.1002/asia.201701258
日期:2017.11.2
Direct C5‐alkylation of oxazole/thiazole with ether or cycloalkane has been achieved through a cobalt‐catalyzed cross‐dehydrogenative coupling (CDC) process in moderate to good yields. This transformation represents the first C(sp2)−C(sp3) cross‐coupling at the C5‐position of the oxazole/thiazole via double C−H bond cleavages. Various functional groups on oxazole/thiazole substrates, as well as water
Iron-catalyzed C(5)−H Imidation of Azole with <i>N</i>
-Fluorobenzenesulfonimide
作者:Xiaojiao Wang、Bowen Lei、Lifang Ma、Huixuan Jiao、Wenhua Xing、Jiaming Chen、Ziyuan Li
DOI:10.1002/adsc.201701124
日期:2017.12.19
An iron(II)‐catalyzed direct imidation of oxazole and thiazole with N‐fluorobenzenesulfonimide (NFSI) through C(5)−H bond cleavage is disclosed, providing C5‐imidated azoles in moderate to excellent yields with broad substrate scope. This reaction represents the first iron‐catalyzed C−Himidation of arene where NFSI serves as the imidation reagent, and potentially constitutes an efficient access to
[EN] 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS THIAZOLES 2-SUBSTITUÉS DE HSD17B13 ET UTILISATIONS ASSOCIÉES
申请人:[en]INIPHARM, INC.
公开号:WO2023146897A1
公开(公告)日:2023-08-03
Described herein are selective HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).
Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity
Piperazine-bisamide analogs were discovered as partial agonists of human growthhormonesecretagoguereceptor (GHSR) in a high throughput screen. The partial agonists were optimized for potency and converted into antagonists through structure–activity relationship (SAR) studies. The efforts also led to the identification of potent antagonist with favorable PK profile suitable as a tool compound for